Clinical efficacy studies should not be the default for biosimilars development, FDA says
As the FDA and other regulators look to streamline the development of new biosimilars further, the US agency is looking to instill in its foreign …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
